Wallwork Named Chairman Of Pulmo BioTech
Wallwork will also be chairing the company's scientific advisory board, where his knowledge and background in pulmonary hypertension as well as his experience in the management of research and development "will be of great benefit," according to the company.
He is currently professor of cardiothoracic surgery and director of research and development at Papworth Hospital NHS Foundation Trust, Cambridge. Before being appointed as a consultant at Papworth Hospital in 1981, he was chief Resident at Stanford University Hospital in Palo Alto, California, for nearly two years, where he first became involved in heart and heart-lung transplantation.
Wallwork performed Europe's first successful heart-lung transplant in 1984 and, with Professor Sir Roy Calne, the world's first heart-lung and liver transplant in 1986. During this period he and his colleague, Tim Higenbottam, were the first to introduce the use of long-term Prostacycline for Primary Pulmonary Hypertension.
He was director of the Transplant Service from 1989 to 2006, chaired the UK Transplant Cardiothoracic Advisory Group from 1994 to 2006 and was medical director of Papworth Hospital from 1997 to 2002. On October 1, 2002 the University of Cambridge awarded him an honorary chair in cardiothoracic surgery.
New York-based Pulmo BioTech is engaged in the development and marketing of medical technology and research. The company is currently developing a non-invasive molecular imaging technique for the diagnosis of pulmonary embolism, pulmonary hypertension and lung inflammatory diseases under the trade name PulmoBind.
FinancialWire" ( http://www.financialwire.net ), an independent, proprietary news service of Investrend Communications, Inc., receives no compensation for its news or opinions. Further disclosure is at http://www.investrend.com/articles/secondlevel.asp?level=472 . To contact FinancialWire" write to inquiries@financialwire.net .
Free annual reports for companies mentioned in the news are accessible via http://investrend.ar.wilink.com/?level=279 .
Copyright(C)2009 by financialwire.net, Inc. All rights reserved.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
